The Western Norway B Vitamin Intervention Trial (Wenbi Tb
Upcoming SlideShare
Loading in...5
×
 

The Western Norway B Vitamin Intervention Trial (Wenbi Tb

on

  • 918 views

B-vitamins intervention trial in stable CAD.

B-vitamins intervention trial in stable CAD.

Statistics

Views

Total Views
918
Views on SlideShare
918
Embed Views
0

Actions

Likes
0
Downloads
1
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

The Western Norway B Vitamin Intervention Trial (Wenbi Tb The Western Norway B Vitamin Intervention Trial (Wenbi Tb Presentation Transcript

  • The Western Norway B-Vitamin Intervention Trial (WENBIT) Ebbing M, Bleie Ø, Ueland PM, et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography. A randomized controlled trial. JAMA . 2008;300:795-804.
  •  
  • Folic Acid and Birth Defects
    • About 2,500 neural tube defects per year in US
    • Occur at 26-28 days post-conception
    • 95% are spontaneous with no family history
    • 1991 UK study showed 71% risk reduction in recurrences (4mg dose)
    • In 1999 (Nov NEJM) 85% reduction in risk for primary prevention (0.4mg dose)
    • Lifetime costs estimated to be $532.000 (2001, MOD)
  • Homocysteine
    • Non-protein-forming, sulfur-containing amino acid
    • Formed exclusively by demethylation of methionine
    • Eliminated through one of two vitamin-dependent pathways, in addition to an alternate vitamin-independent pathway in liver
  • Hyperhomocystinemia
    • Independent risk factor for atherosclerotic and thromboembolic disease
    • A 5 µM increase in serum level confers a 80% increased risk to women and a 60% increased risk to men for atherosclerotic vascular disease
    • In patients with coronary artery disease, serum homocysteine levels increase with the number of stenosed coronary vessels
    • Hyperhomocystinemia may reflect:
      • Genetic defects
      • Folate (most common), pyridoxine (vitamin B 6 ), or cobalamin (vitamin B 12 ) deficiencies
      • Renal failure
    • Serum levels of homocysteine may be lowered by supplementation with folate, vitamin B 6 , and vitamin B 12
  •  
  •  
  • DESIGN
    • In this randomized, double-blind, controlled trial, 3096 adult participants undergoing coronary angiography (20.5% women; mean age, 61.7 years) were randomly selected.
    • With use of a 2 x 2-factorial design, participants were randomly assigned to 1 of 4 groups
    • receiving daily oral treatment with folic acid (0.8 mg) plus vitamin B 12 (0.4 mg) and vitamin B 6 (40 mg; n = 772);
    • folic acid plus vitamin B 12 (n = 772);
    • vitamin B 6 alone (n = 772);
    • or placebo (n = 780).
  • BASELINE
    • At baseline,
    • 59.3% had double- or triple-vessel disease,
    • 83.7% had stable angina pectoris,
    • and 14.9% had acute coronary syndromes.
  • The primary endpoint
    • was a composite of all-cause death, nonfatal acute myocardial infarction, acute hospitalization for unstable angina pectoris, and nonfatal thromboembolic stroke.
  • The trial was terminated early Median follow-up was 38.4 months NORVIT,
    • The trial was terminated early because of concern among participants due to preliminary results from a contemporaneous Norwegian trial suggesting adverse effects from the intervention.
  • Mean plasma total homocysteine
    • Mean plasma total homocysteine concentration was reduced by 30% after 1 year of treatment in the groups receiving folic acid and vitamin B 12 ( P < 0.01).
  • Secondary endpoints
    • were fatal and nonfatal acute myocardial infarction, acute hospitalization for angina pectoris, stable angina pectoris with angiographically verified progression, myocardial revascularization procedures, and fatal and nonfatal stroke
  • WENBIT: Percentage of patients with cardiovascular events Ebbing M et al. JAMA 2008; 300:795-804. End point Folic acid+B 12 +B 6 Folic acid+B 12 B 6 Placebo Primary end point 12.2 16.3 13.7 12.5 All-cause death 4.5 4.9 3.6 3.9 Acute MI 7.7 9.9 7.1 7.4 Unstable angina 2.9 3.8 3.1 3.5 Nonfatal thromboembolic stroke 1.4 2.2 2.6 2.4 Cancer 6.0 5.1 4.9 4.0
  • There were no differences in treatment response for the separate endpoints of death, total acute myocardial infarction, or unstable angina. The incidence of total stroke was lower in the groups receiving folic acid; however, this observation was not statistically significant. The incidence of acute hospitalization for angina pectoris was lower in the folic acid groups, reaching borderline statistical significance ( P = .05).
    • The incidence of cancer was higher in the groups receiving folic acid; however, this finding was not statistically significant.
    • There were no differences in the rates of adverse effects among the 4 intervention groups and no report of serious adverse events related to study medication.